多家医院儿科急诊量明显上升 低龄儿童抗病毒流感用药有望迎来新选择

Core Viewpoint - There is a significant increase in pediatric emergency visits due to influenza, particularly among children under 5 years old, highlighting the urgent need for effective antiviral treatments for this demographic [1][2]. Group 1: Pediatric Influenza Situation - Recent data from multiple hospitals in Shanghai indicates a notable rise in pediatric emergency visits, primarily due to influenza cases, with a reported 20% increase in emergency visits at Shanghai Jiao Tong University Affiliated Xinhua Hospital [1]. - The H3N2 strain of influenza is particularly concerning this year, as it has a faster mutation rate and higher transmissibility compared to last year's H1N1 strain, leading to increased risks of severe respiratory complications in children [1]. - Children under 5 years old represent a high-risk group for severe influenza complications, with a reported incidence rate that is over three times higher than that of the 15 to 59 age group [1]. Group 2: Antiviral Treatment Landscape - Current antiviral treatment options for influenza in children under 5 years are limited, with only neuraminidase inhibitors like Oseltamivir approved for use, which can cause side effects such as nausea and vomiting [1]. - There is a rising trend in antiviral resistance, indicating a significant unmet need for effective antiviral treatments for young children [1]. - Recent clinical research led by a team from Capital Medical University has evaluated the safety and efficacy of Marbofloxacin suspension for influenza in children aged 1 to under 5 years, potentially expanding treatment options for this age group [2]. - The market for pediatric influenza antiviral medications is expanding, with new products like the RNA polymerase inhibitor, Madurosavir, being developed specifically for children aged 2 to 11 years [2].